- Home
- ZNTL vs DIBS Comparison
ZNTL vs DIBS Comparison
Compare ZNTL & DIBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- DIBS
- Stock Information
- Founded
- ZNTL 2014
- DIBS 2000
- Country
- ZNTL United States
- DIBS United States
- Employees
- ZNTL N/A
- DIBS N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- DIBS Catalog/Specialty Distribution
- Sector
- ZNTL Health Care
- DIBS Consumer Discretionary
- Exchange
- ZNTL Nasdaq
- DIBS Nasdaq
- Market Cap
- ZNTL 134.7M
- DIBS 132.5M
- IPO Year
- ZNTL 2020
- DIBS 2021
- Fundamental
- Price
- ZNTL $2.32
- DIBS $4.05
- Analyst Decision
- ZNTL Buy
- DIBS Buy
- Analyst Count
- ZNTL 8
- DIBS 2
- Target Price
- ZNTL $8.53
- DIBS $8.00
- AVG Volume (30 Days)
- ZNTL 2.7M
- DIBS 77.9K
- Earning Date
- ZNTL 03-04-2025
- DIBS 02-28-2025
- Dividend Yield
- ZNTL N/A
- DIBS N/A
- EPS Growth
- ZNTL N/A
- DIBS N/A
- EPS
- ZNTL N/A
- DIBS N/A
- Revenue
- ZNTL $40,560,000.00
- DIBS $86,409,000.00
- Revenue This Year
- ZNTL N/A
- DIBS $5.17
- Revenue Next Year
- ZNTL N/A
- DIBS $7.90
- P/E Ratio
- ZNTL N/A
- DIBS N/A
- Revenue Growth
- ZNTL N/A
- DIBS N/A
- 52 Week Low
- ZNTL $1.61
- DIBS $3.37
- 52 Week High
- ZNTL $18.07
- DIBS $6.30
- Technical
- Relative Strength Index (RSI)
- ZNTL 49.24
- DIBS 57.88
- Support Level
- ZNTL $2.37
- DIBS $3.99
- Resistance Level
- ZNTL $2.36
- DIBS $4.25
- Average True Range (ATR)
- ZNTL 0.25
- DIBS 0.13
- MACD
- ZNTL 0.08
- DIBS -0.00
- Stochastic Oscillator
- ZNTL 69.27
- DIBS 50.00
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company's single reportable and operating segment contains two reporting units; 1stDibs, which consists of the company's online marketplace that enables commerce between sellers and buyers; and Design Manager, which is the company's separate online platform that is used to sell a software solution to interior designers. It generates revenue primarily from fees from seller marketplace services as well as other services, including advertisements and software services.